Frequency of poor risk cytogenetics (according to IPSS) in morphologically defined MDS subgroups (FAB and WHO)
| Groups compared . | No. . | Cases with unfavorable karyotype according to IPSS, no. (%) . | P (χ2 value) . |
|---|---|---|---|
| FAB | |||
| RA vs | 573 | 76 (13) | .25 (1.30) |
| RARS | 252 | 41 (16) | |
| RAEB vs | 415 | 133 (32) | .94 (0.00) |
| RAEB-t | 305 | 97 (32) | |
| RA + RARS vs | 825 | 117 (14) | < .001 (69.65) |
| RAEB + RAEB-t | 720 | 230 (32) | |
| RAEB + RAEB-t vs | 720 | 230 (32) | .32 (0.99) |
| AML | 132 | 48 (36) | |
| WHO | |||
| RA vs | 56 | 9 (16) | .03 (4.69) |
| RARS | 26 | 0 (0) | |
| RCMD vs | 164 | 33 (20) | .15 (2.12) |
| RSCMD | 77 | 22 (29) | |
| RAEB-I vs | 90 | 28 (31) | .19 (1.68) |
| RAEB-II | 121 | 28 (23) | |
| RA + RARS vs | 82 | 9 (11) | .03 (4.68) |
| RCMD + RSCMD | 241 | 55 (23) | |
| RA + RARS vs | 82 | 9 (11) | .006 (7.41) |
| RAEB-I + RAEB-II | 211 | 56 (27) | |
| RCMD + RSCMD vs | 241 | 55 (23) | .36 (0.84) |
| RAEB-I + RAEB-II | 211 | 56 (27) |
| Groups compared . | No. . | Cases with unfavorable karyotype according to IPSS, no. (%) . | P (χ2 value) . |
|---|---|---|---|
| FAB | |||
| RA vs | 573 | 76 (13) | .25 (1.30) |
| RARS | 252 | 41 (16) | |
| RAEB vs | 415 | 133 (32) | .94 (0.00) |
| RAEB-t | 305 | 97 (32) | |
| RA + RARS vs | 825 | 117 (14) | < .001 (69.65) |
| RAEB + RAEB-t | 720 | 230 (32) | |
| RAEB + RAEB-t vs | 720 | 230 (32) | .32 (0.99) |
| AML | 132 | 48 (36) | |
| WHO | |||
| RA vs | 56 | 9 (16) | .03 (4.69) |
| RARS | 26 | 0 (0) | |
| RCMD vs | 164 | 33 (20) | .15 (2.12) |
| RSCMD | 77 | 22 (29) | |
| RAEB-I vs | 90 | 28 (31) | .19 (1.68) |
| RAEB-II | 121 | 28 (23) | |
| RA + RARS vs | 82 | 9 (11) | .03 (4.68) |
| RCMD + RSCMD | 241 | 55 (23) | |
| RA + RARS vs | 82 | 9 (11) | .006 (7.41) |
| RAEB-I + RAEB-II | 211 | 56 (27) | |
| RCMD + RSCMD vs | 241 | 55 (23) | .36 (0.84) |
| RAEB-I + RAEB-II | 211 | 56 (27) |